Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 490 Rectal Neoplasms 267 Colonic Neoplasms 218 Pancreatic Neoplasms 184 Stomach Neoplasms 181 Esophageal Neoplasms 134 Breast Neoplasms 118 Neoplasm Metastasis 116 Squamous Cell Carcinoma of Head and Neck 94 Head and Neck Neoplasms 92 Neoplasms 88 Adenocarcinoma Of Esophagus 67 Esophageal Squamous Cell Carcinoma 61 Carcinoma, Hepatocellular 54 Adenocarcinoma 40 Nasopharyngeal Carcinoma 33 Cholangiocarcinoma 31 Biliary Tract Neoplasms 26 Anus Neoplasms 26 Gastrointestinal Neoplasms 25 Carcinoma, Squamous Cell 25 Carcinoma, Non-Small-Cell Lung 25 Keratosis, Actinic 22 Gallbladder Neoplasms 21 Urinary Bladder Neoplasms 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 20 Liver Neoplasms 20 Bile Duct Neoplasms 19 Ovarian Neoplasms 16 Carcinoma 16

Interventions

Nivolumab 5 Ipilimumab 3 relatlimab 1 daratumumab 1 Fluorouracil 1 Cisplatin 1 BMS-986115 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Various Advanced Cancer × Fluorouracil × Clear all

NCT03143153 2026-02-17

CheckMate 648

Bristol-Myers Squibb

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡